chrX-101349783-AG-A
Position:
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BS1_SupportingBS2
The NM_000061.3(BTK):c.*101del variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000143 in 699,423 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 2 hemizygotes in GnomAD. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.0000090 ( 0 hom., 0 hem., cov: 22)
Exomes 𝑓: 0.000015 ( 0 hom. 2 hem. )
Consequence
BTK
NM_000061.3 3_prime_UTR
NM_000061.3 3_prime_UTR
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 0.416
Genes affected
BTK (HGNC:1133): (Bruton tyrosine kinase) The protein encoded by this gene plays a crucial role in B-cell development. Mutations in this gene cause X-linked agammaglobulinemia type 1, which is an immunodeficiency characterized by the failure to produce mature B lymphocytes, and associated with a failure of Ig heavy chain rearrangement. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Dec 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -5 ACMG points.
BS1
Variant frequency is greater than expected in population amr. gnomad4_exome allele frequency = 0.0000153 (9/588102) while in subpopulation AMR AF= 0.000297 (9/30293). AF 95% confidence interval is 0.000154. There are 0 homozygotes in gnomad4_exome. There are 2 alleles in male gnomad4_exome subpopulation. Median coverage is 9. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
BS2
High Hemizygotes in GnomAdExome4 at 2 XL gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BTK | NM_000061.3 | c.*101del | 3_prime_UTR_variant | 19/19 | ENST00000308731.8 | NP_000052.1 | ||
BTK | NM_001287344.2 | c.*101del | 3_prime_UTR_variant | 19/19 | NP_001274273.1 | |||
BTK | NM_001287345.2 | c.*101del | 3_prime_UTR_variant | 17/17 | NP_001274274.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BTK | ENST00000308731.8 | c.*101del | 3_prime_UTR_variant | 19/19 | 1 | NM_000061.3 | ENSP00000308176 | P3 |
Frequencies
GnomAD3 genomes AF: 0.00000898 AC: 1AN: 111321Hom.: 0 Cov.: 22 AF XY: 0.00 AC XY: 0AN XY: 33519
GnomAD3 genomes
AF:
AC:
1
AN:
111321
Hom.:
Cov.:
22
AF XY:
AC XY:
0
AN XY:
33519
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.0000153 AC: 9AN: 588102Hom.: 0 Cov.: 9 AF XY: 0.0000114 AC XY: 2AN XY: 175992
GnomAD4 exome
AF:
AC:
9
AN:
588102
Hom.:
Cov.:
9
AF XY:
AC XY:
2
AN XY:
175992
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00000898 AC: 1AN: 111321Hom.: 0 Cov.: 22 AF XY: 0.00 AC XY: 0AN XY: 33519
GnomAD4 genome
AF:
AC:
1
AN:
111321
Hom.:
Cov.:
22
AF XY:
AC XY:
0
AN XY:
33519
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 11, 2016 | Variant summary: The c.*101delC in BTK gene is a deletion of conserved nucleotide in 3' UTR region. Mutation Taster algorithm predicts this change to not affect a poly(A) signal, however, no stability studies were published at the time of evaluation. The presence of the variant in the general population could not be determined at this time as this region is not covered the control population dataset of ExAC and has not, to our knowledge, been reported in affected individuals via published reports or by reputable databases/clinical laboratories. An internal subject (famale) carrying this variant also carried c.799_806delAACTATGTT (evaluated as likely pathogenic); however, phase of the variants are unknown. Taken together, the variant was classified as VUS. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at